Patient stories

      Test
      Focus Area
      Format
      Evidence
FILTER BY TESTS
DecisionDx-Melanoma DecisionDx-SCC MyPath Melanoma TissueCypher DecisionDx-UM IDgenetix
Click to play "The Limitations of Traditional Approaches" video

The Limitations of Traditional Approaches

Using staging systems alone may miss patients with aggressive tumor biology. Listen in, to learn how DecisionDx-Melanoma addresses these limitations by improving prognostic accuracy.

DecisionDx-Melanoma
Watch Story Link icon
Click to play "A Life Changing Prognosis of Uveal Melanoma: Kevin's Story" video

A life-changing prognosis of uveal melanoma: Kevin’s story

After being diagnosed with uveal (or ocular) melanoma, Kevin was directed to explore the benefits and indications of Castle Biosciences' DecisionDx-UM gene expression profile (GEP) test, which predicts a patient’s risk based upon their tumor’s own unique biology. The findings of the test, Kevin says, "were of huge importance to myself and my family. They put me at rest and we could all move on. The Castle's uveal melanoma prognostic platform can truly be life-changing."

Uveal Melanoma DecisionDx-UM
View More Link icon
Click to play "Katherina Alsina, PhD - Castle Biosciences Genomic Testing for Uveal Melanoma" video

AHNS DecisionDx–SCC Webinar: Identifying the Risk of Metastasis in cSCC and cSCC-HN Patients

DecisionDx-SCC
Watch Story Link icon
Click to play "Katherina Alsina, PhD - Castle Biosciences Genomic Testing for Uveal Melanoma" video

Katherina Alsina, PhD - Castle Biosciences Genomic Testing for Uveal Melanoma

DecisionDx-UM
Watch Story Link icon